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The recent approvals of immunotherapeutic agents (Sipuleucel-T and Ipilimumab) for the
treatment of different solid tumors gave a boost to the growing cancer immunotherapy
field, even though few immunotherapy studies have demonstrated convincingly that there
is a direct link between the predicted mode of action of an immunological compound and
therapeutic benefit. MVA-5T4 (TroVax®) is a novel vaccine combining the tumor-associated
antigen 5T4 to an engineered vector-modified vaccinia Ankara (MVA). MVA helps to express
the oncofetal 5T4 antigen and subsequently trigger a tumor-directed immune reaction.The
safety and clinical benefit reported in multiple phase I and II clinical trials using MVA-
5T4 were encouraging; immune responses were induced in almost all treated patients,
and associations between 5T4-specific cellular or humoral responses and clinical benefit
were reported in most of the nine phase II trials. In particular, clinical studies conducted
in renal cell carcinoma (RCC) patients have demonstrated an association between 5T4-
specific (but not MVA) antibody responses and enhanced survival. This review describes
the clinical studies using MVA-5T4 conducted in RCC that convincingly demonstrated that
an antigen-specific immune response induced by vaccination is associated with enhanced
patient survival and is not simply a function of the general “health” of patients. We will
also provide our expert opinions on possible future better-designed clinical trials based on
relevant biomarkers. In addition, various combinations of MVA-5T4 and different and newer
immunomodulator agents with promising clinical benefit will be discussed.
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INTRODUCTION
The incidence of renal cell carcinoma (RCC) varies widely from
region to region, with the highest rates observed in North America
and Czech Republic (1). It is the tenth most common cancer in
Europe (2). In the United States, there are approximately 65,000
new cases and almost 14,000 deaths from RCC each year (3). RCC
includes several different histologic subtypes that possess distinct
biological behaviors and prognoses. Approximately 75% of all
RCCs are of the clear cell type, which is associated with the worst
prognosis (4). Advanced RCC is highly resistant to chemother-
apy, and cytotoxic drugs generally only have a small effect on
tumors in a very selective subgroup (5, 6). In a small percentage of
patients, high-dose interleukin-2 (IL-2) can be very effective, but
it is poorly tolerated (7). Recent research has focused on develop-
ing molecular-targeted therapies (e.g., sunitinib, sorafenib, beva-
cizumab, axitinib, temsirolimus, and pazopanib), many of which
have been approved for the treatment of metastatic RCC. The role
of vaccine therapy in the management of various solid tumors,
including RCC, is rapidly evolving; HSPPC-96 (Vitespen®), pro-
tein peptide complex consisting of a 96-kDa heat-shock protein,
was tested in a phase III clinical trial and showed some clinical
benefit in terms of increased recurrence-free survival in patients
with intermediate risk (8); in fact, this agent is currently approved
in Russia for treatment of RCC (9). IMA-901, a novel vaccine
consisting of 10 synthetic tumor-associated peptides, is currently
being studied in combination with either sunitinib, cyclophos-
phamide (CY), or granulocyte macrophage-colony stimulating
factor (GM-CSF) in a phase III trial (NCT01265901).
Currently, the standard of care (SOC) for non-metastasized
RCC includes cytoreductive surgery without any adjuvant treat-
ment outside clinical trial setting, while the SOC for metastasized
RCC include cytoreductive surgery, if feasible, followed by any
of the various molecular-targeted therapies (10). In addition to
the anatomical extent of the disease, other poor prognosis fac-
tors, including a low Karnofsky performance status (<80%), high
serum lactate dehydrogenase (>1.5 times upper limit of normal),
low hemoglobin (<lower limit of normal), high“corrected”serum
calcium (>10 mg/dL), and absence of prior nephrectomy, have
been validated as predicting shorter overall survival (11, 12).
Although newer targeted agents improve the overall outcome of
patients with RCC, the median survival of patients with advanced
disease is still relatively poor (13). Therefore, new agents for the
treatment of RCC are needed. Vaccine therapy is a growing class
of drugs for the treatment of various cancers, including RCC.
The development of cancer vaccines has also been explored using
viral vectors to promote immune responses against tumor-specific
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antigens (14, 15). Viral vector-based vaccine therapy involves iden-
tifying (i) tumor-associated antigens (TAAs) and (ii) the most
suitable delivery system. Cancer cells generally show some degree
of genetic instability (16), which can lead to the production of
an assortment of aberrant proteins that are hypo- or hyper-
glycosylated as well as highly expressed or expressed during the
wrong development stage (17). An optimal TAA is minimally
expressed (if at all) in normal tissue yet still has homogenous
high-level expression on the surface of a broad range of tumors.
In particular, TAAs that are associated with disease progression are
optimal because they actively interfere with tumorigenesis in addi-
tion to attacking the tumor. Once a TAA is selected, the method of
delivering it to the immune system must be considered. Proteins
expressed by carcinomas are usually presented to the immune sys-
tem as self-proteins, which elicit no immune response (18). By
contrast, using a viral delivery system breaks self-tolerance and
elicits an immune response to the TAA.
One of the most commonly used viral delivery system is modi-
fied vaccinia Ankara (MVA) because of its well-documented safety
profile and proven ability to generate potent immune responses
(19, 20). A promising TAA is the 5T4 antigen, which is normally
expressed in the placenta and rarely detected on most normal adult
tissue (21, 22), although it is highly expressed in a range of human
carcinomas (23–25).
THE VACCINE
MVA-5T4 (TroVax®) is a novel vaccine, using MVA as a vector,
which was engineered to induce the expression of the oncofetal
5T4 TAA on tumor cells. Subsequently, the vaccine can break the
immune tumor tolerance through the induction of cellular and
humoral responses to both MVA and 5T4; therefore, it provides
protection against 5T4-positive tumors (26, 27).
Tumor-associated antigens belong to one of three major cat-
egories: (i) non-self-viral antigens (e.g., E6/E7 from human
papilloma virus), (ii) altered self-antigens (e.g., MUC-1), and
(iii) non-mutated self-antigens (e.g., carcinoembryonic antigen).
Human 5T4 belongs to the non-mutated self-antigens category.
The 5T4 antigen is a 72-kDa transmembrane glycoprotein with an
extracellular part composed of leucine-rich repeat domains sep-
arated by hydrophilic amino acids with 7 N-linked glycosylation
sites (28, 29). The 5T4 antigen is normally highly expressed in the
placenta but is also highly expressed in>80% of breast, renal, col-
orectal, prostate, and ovarian carcinomas (22, 30). Although the
precise function of 5T4 in tumorigenesis has yet to be elucidated,
in vitro human and murine studies have found that 5T4 is con-
centrated at the microvillus projections of the plasma membrane
and that the overexpression of 5T4 alters cell adhesion, motility,
and morphology (31). Overall, studies have shown that tumors
expressing 5T4 antigen are associated with poor clinical outcome
(23, 32–35).
Modified vaccinia Ankara is a highly attenuated strain of vac-
cinia virus – a member of the poxvirus family – that is unable
to replicate in most mammalian cells (36). MVA was derived as a
safe smallpox vaccine that showed no serious side effects; infected
mammalian cells efficiently produce products of both early and
late viral genes, as the block in viral replication occurs during
virion assembly (37). In addition, its large double-stranded DNA
genome is likely to accommodate >25 kb of foreign DNA (38).
MVA-5T4 has shown therapeutic effectiveness in preclinical
models (39) as well as in clinical trials of patients with various
solid tumors, including colorectal and prostate cancer (40–44).
Herein, we will review all the clinical trials conducted in patients
with metastatic RCC (mRCC; see Table 1). We will focus on both
cellular and humoral immunologic responses and their correlation
Table 1 | Summary of all clinical trials conducted using MVA-5T4 in the treatment of mRCC.
Study
design
Treatment Number of
patients
Number of
injections
MVA antibody
response,
*no. (%)
5T4-antibody
response,
*no. (%)
MVA ELISPOT,
*no. (%)
5T4 ELISPOT,
*no. (%)
Clinical
benefit
(RECIST)
Hawkins
et al. (45)
Phase I/II MVA-
5T4+ INF-α
11 11 11 (100) 11 (100) 11 (100) 5 (45) None
Amato
et al. (48)
Phase II MVA-
5T4+ INF-α
vs. MVA-5T4
28 9 25 (100) 21 (84) 14 (66) 7 (33) PR: 1,
SD¤: 5
Amato
et al. (46)
Phase II MVA-
5T4+ IL-2
25 8 25 (100) 21 (84) 6 (54) 5 (45) CR: 2, PR:
1, SD¤: 6
Kaufman
et al. (47)
Phase II MVA-
5T4+ IL-2
25 8 23 (100) 23 (100) 23 (100) 13 (57) CR§: 3
Amato
et al. (49)
Phase III MVA-
5T4+ IL-2,
INF-α or
sunitinib
733 13 350 (96) 204 (56) – – CR: 2, PR:
47, SD¤:
173
*Not all patients enrolled were tested. §One patient had two abdominal masses that were removed surgically after regression, and two patients had complete
regression of all metastatic sites after vaccine therapy and later underwent nephrectomy of the primary tumors. ¤Patients had SD for ≥6months. CR, complete
response; PR, partial response; SD, stable disease.
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to the tumor response. We also will provide expert opinions for
the better design of future clinical trials.
CLINICAL TRIALS
PHASE I/II STUDIES
An open-label phase I/II study was conducted in 11 mRCC patients
who were receiving first-line systemic therapy (45). Patients with
RCC received MVA-5T4 alongside interferon (IFN)-α. The pri-
mary objectives were to evaluate the safety, immunogenicity, and
efficacy of the combination therapy. The treatment was well tol-
erated, and no significant adverse events were attributed to the
treatment. The only MVA-5T4-related adverse event was sore-
ness at the injection site. All patients mounted either boosted
or de novo MVA-specific and 5T4-specific antibody responses as
monitored by ELISA. The peak 5T4 and MVA antibody titers
were achieved after 3–4 TroVax injections and remained con-
stant thereafter. The IFN-γ enzyme-linked immunosorbent spot
(ELISPOT) response was used to monitor antigen-specific cel-
lular responses. There was no evidence that patients with pre-
existing MVA antibody had diminished 5T4-specific antibody
response. All patients mounted MVA-specific ELISPOT responses,
and six patients (54.5%) showed a greater than twofold increase
in comparison to baseline. Out of 11 patients, 5 (45%) devel-
oped a 5T4-specific response. The median time to progression was
9 months (range, 2.1–18 months). No objective tumor responses
were observed.
Three phase II clinical trials were conducted using MVA-5T4
in combination with IFN-α (46) and with IL-2 (46, 47). In a
phase II clinical trial using MVA-5T4 with (n= 15) or without
IFN-α (n= 13), safety, the immunologic response, and clinical
efficacy were tested (48). As in the study described earlier, MVA-
5T4 was found to be safe, without any serious adverse events or
dose reduction. Immunological responses (cellular and humoral)
of 23 patients showed that 91% (n= 21) and 100% (n= 23) of
patients mounted boosted and de novo 5T4-specific and MVA-
specific antibody response, respectively. Patients with preexisting
MVA-specific antibody (n= 13) did not have a diminished 5T4-
specific response. The IFN-γ ELISPOT assay performed on 21
patients showed that 14 of them had a≥twofold increase (positive)
in MVA-specific response. Out of 21 patients, 7 (33%) mounted
a 5T4-specific ELISPOT response, including 1 patient with a
weak (<fourfold increase) response. More patients mounted a
specific-5T4 response in the MVA-5T4 group than in the com-
bined group, but this was not statistically significant (38 vs. 25%).
With respect to response to treatment, one patient in the com-
bination group had a partial response (PR) lasting 7 months. No
objective response was seen in the MVA-5T4-alone group. Over-
all, 14 patients (7 in each arm) had stable disease (SD), of whom 5
had SD for>6 months. The median PFS was 3.73 vs. 6.07 months
(p= 0.13) and the median OS was 5.93 vs. 18.27 months (p= 0.02)
for the group receiving MVA-5T4 with IFN-α vs. MVA-5T4 alone.
In addition, the median PFS was 10.2 months for patients who
mounted a positive 5T4-specific ELISPOT response vs. 4.5 months
for patients who did not (p= 0.04). OS was also increased in
patients who mounted a positive 5T4-specific ELISPOT response,
but this was not statistically significant (p= 0.21). Further analy-
sis showed that patients with increases in 5T4 antibodies at week
7 (after the third vaccination) above the median fold showed a
trend toward increased PFS and a significant improvement in
OS (p= 0.01) compared to patients with antibody levels below
the median. Correlations between outcome and MVA-specific
antibody response using the same analysis were negative.
In a phase II open-label study, Amato et al. tested the safety,
immunologic response, and clinical efficacy of MVA-5T4 vaccine
in combination with IL-2 in mRCC (46). Twenty-five patients were
enrolled in the study. MVA-5T4 was found to be safe with no seri-
ous adverse events or dose reductions. Out of 25 patients, 21 (84%)
developed an antibody to 5T4, and all patients (100%) mounted
MVA-specific antibody responses. The peak of both anti-5T4 and
-MVA antibodies was achieved after three vaccine injections and
remained relatively stable thereafter. Out of 11 patients, 6 (54%)
and 5 (45%) showed positive MVA- and 5T4-specific ELISPOT
responses, respectively.
Nine patients experienced a clinical benefit, including three
patients (12%) with objective tumor responses (two CR and one
PR) and six patients (24%) with SD for >6 months. Patients with
objective responses mounted 5T4-specific antibody titers after
three vaccinations that were higher than the overall median titer.
The median PFS was 3.37 months (range, 1.5–24.76 months), and
the median OS was 12.87 months (range, 1.90–24.76 months). The
correlation between clinical and immunological responses showed
significant differences in PFS among patients whose 5T4-antibody
response was above the median compared with those whose 5T4-
antibody response was below median (quantified between weeks 2
and 18; p= 0.015), but this was not true for the MVA antibody
response. The OS data was immature, but a significant differ-
ence in OS was observed in patients whose 5T4-antibody response
was above the median compared with those whose 5T4-antibody
response was below the median between weeks 2 and 5 (p= 0.04);
again, this was not the case for the MVA antibody response. The
authors concluded that the combination of MVA-5T4 and IL-2
was well tolerated and safe, and the combination was planned for
study in a phase III trial.
Another trial was conducted to test the efficacy of MVA-5T4
vaccination with IL-2 in 25 patients with mRCC (47). Patients were
given the vaccine initially and then received a booster with IL-2
3 weeks later. Out of 25 patients, one patient withdrew from the
trial (due to relocation), and another patient could not tolerate IL-
2. The MVA-5T4 was well tolerated with no serious adverse events.
All patients mounted boosted or de novo MVA- and 5T4-specific
antibody responses as measured by ELISA. The IFN-γ ELISPOT
assay showed a positive 5T4-specific response in 13 patients (57%)
(SD, n= 10 vs. PD, n= 3) and an MVA-specific response in all
patients.
Four-color flow cytometry showed that patients with SD
had greater increase in CD8+CD107a+ T-cells than those with
PD (1.50± 0.72 vs. 2.09± 0.30%, p= 0.015). Patients with PD
showed significantly higher levels of PD-1 expressing CD4+
(p= 0.0329) and CD8+ T-cells (p= 0.0373) than patients with
SD at 3 weeks. The absolute number of regulatory T-cells (TREGs)
(CD4+CD25+FoxP3+) was decreased by 50% in patients with
SD (p= 0.006). The effector/regulatory T-cell ratio was decreased
in patients with PD but was both dramatically increased and
maintained for up to 24 months in patients with SD.
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The median PFS was 4.76 months, and the median OS was
28 months for patients with PD but had not yet reached for patients
with SD at a median follow-up of 20 months (n= 12; p= 0.0206).
The authors concluded that MVA-5T4 vaccine plus IL-2 can be
safely given to patients with mRCC. Patients with SD were asso-
ciated with increased levels of effector T-cells and decreased levels
of TREGs cells, which is suggestive a benefit from therapy.
PHASE III STUDIES
To date, one phase III trial has been completed for MVA-5T4
in RCC patients (49). This randomized, double-blind, placebo-
controlled study included 733 patients (365 MVA-5T4, 368
placebo) with mRCC. The primary endpoint was OS, and the
secondary endpoints were PFS, objective response rate, and safety.
Patients received up to 13 injections of MVA-5T4 or placebo in
combination with one of the following: low-dose IL-2, IFN-α,
or sunitinib. The study was terminated at the recommendation
of the safety monitoring board because there was little or no
prospect of demonstrating a significant survival benefit; however,
patient follow-up continued. The median time on the study was
6 months, and only 5% of patients received a complete course
of injections (n= 13). For patients who received IL-2 or IFN-α,
the median number of MVA-5T4/placebo injections was eight,
and for patients who received sunitinib, the median number of
MVA-5T4/placebo injections was seven. The median OS was 20.1
and 19.2 months for the MVA-5T4 and placebo treatment arms,
respectively. Patients with a good prognosis according to Memorial
Sloan-Kettering Cancer Center (MSKCC) guidelines and who were
treated with MVA-5T4 plus IL-2 showed significantly improved
survival over those with a good prognosis who were treated with
the placebo plus IL-2. The effect on OS of clinical baseline features
and known prognostic risk factors was analyzed using a Cox pro-
portional hazards model. It was noted that normal baseline levels
of platelets (≤400× 109 cells/L), monocytes (≤0.80× 109 cells/L),
and hemoglobin (age- and sex-specific ranges) seemed to affect
the efficacy of MVA-5T4. Antibody responses against 5T4 and
MVA were quantified, and patients who had a high 5T4-antibody
response had improved survival over placebo-treated patients.
In comparison, patients who had a high MVA-specific antibody
response had no survival benefit compared to placebo-treated
patients. Although the study results demonstrated that MVA-
5T4 did not prolong survival when added to SOC therapies, this
study revealed immune response surrogates that predicted longer
survival, including normal pretreatment levels of platelets, mono-
cytes, and hemoglobin. In addition, this phase III trial confirmed
previous data reported in phase II trials that showed an association
between 5T4 (but not MVA) antibody development and improved
survival.
The data on numerous pretreatment factors associated with
inflammatory anemia from this large phase III trial were later
reanalyzed using a statistical modeling and showed that mean
corpuscular hemoglobin concentration (MCHC) was the best pre-
dictor of a treatment benefit from MVA-5T4 (p< 0.01); this value
was also positively correlated with tumor shrinkage (p< 0.001)
and positively associated with 5T4-antibody response (50). These
data were validated retrospectively using the data from phase II
trials of MVA-5T4 in patients with colorectal, renal, and prostate
cancers. In addition, tumor burden was found to be negatively
correlated with MVA-5T4 treatment (50).
DISCUSSION
MVA-5T4 is a novel vaccine therapy that was engineered to express
the 5T4 tumor-associated antigen, to break the immune tolerance
toward tumor cells, and ultimately to treat various solid tumors.
Preclinical data have shown encouraging results. Furthermore,
early-phase I/II trials confirmed its safety profile with minimal
grade 1–2 side effects. In addition to its safety profile, clinical
effectiveness was noted in RCC, prostate cancer, and colorectal
cancer. Early-phase clinical trials also showed a preliminary pos-
itive correlation between immune response to 5T4 and clinical
outcome. Currently, this vaccine is being studied in mesothelioma
(NCT01569919) and ovarian carcinoma (NCT01556841).
Unfortunately, the positive results seen in phase I/II clinical tri-
als were not replicated and validated in the phase III clinical trial
when MVA-5T4 was added to the SOC. Even though the phase III
trial did not meet its endpoints, several points in the trial’s design
need to be highlighted that might explain the less-than-expected
results: (a) minimal imbalances in prognostic factors were not in
favor of the MVA-5T4 arm; (b) the choice of the SOC was based on
the local best practices; (c) the futility stopping rule was termina-
tion of MVA-5T4 treatment after a median time on study of only
6 months, which would affect the overall outcome given the fact
that immunotherapy, unlike chemotherapy, has a delayed response
(51); (d) the dosing and boosting schedule of MVA-5T4 might not
have been optimal and a more accelerated schedule could be nec-
essary in light of the fact that the T-cell responses after two or three
vaccinations could be transient, as was seen in some of the earlier
studies (40, 41); and (e) the role of predictive biomarkers to select
patients for MVA-5T4 treatment is critical, especially given that
the group with good MSKCC prognostic scores did very well with
the IL-2+MVA-5T4 treatment.
In addition to the MSKCC prognostic score, further analyses of
the data from all these clinical trials have shown that biomarkers
including normal levels of platelet counts, hemoglobin and mono-
cytes, and MCHC might predict a better outcome with MVA-5T4
treatment. Furthermore, the expression of 5T4 on tumor cells as a
predictive biomarker for response to MVA-5T4 needs to be eval-
uated and studied. Determining the expression of 5T4 requires
tumor tissue, which might be difficult in some settings; testing 5T4
on circulating tumor cells needs to be explored as an option that
does not require tissue banking. All of these biomarkers should be
considered in any future clinical trial design using MVA-5T4.
In addition to including the role of predictive biomarkers in
future clinical trials design, the combination of MVA-5T4 with
other immunomodulator agents in the treatment of RCC (and
probably other solid tumors) will be of great interest and at least
theoretically might add clinical benefit. Herein, we will propose
some of the combinations that we think it is worthwhile to pursue.
The combination of MVA-5T4 with GM-CSF was previously
studied in hormone-refractory prostate cancer, and it showed a
high frequency of 5T4-specific immune responses that were cor-
related with longer time to progression (44). GM-CSF has demon-
strated clinical benefit in the treatment of cancer patients on
the basis of their immunomodulatory properties (enhancement
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of monocyte-mediated and dendritic cell-mediated antibody-
dependent cellular cytotoxicity and T-cell cross priming) (52–54).
This combination should be studied in mRCC, in which apopto-
sis of T-cells has been previously reported as an immune escape
mechanism (55, 56).
TREGs account for 5–10% of CD4+ T-cells, and they constitu-
tively express CD25 (57). TREGs control the key aspects of immune
tolerance and play an important role in the lack of antitumor
immune responses (58). CY is a chemotherapeutic agent with a
dual effect on immune system: low-dose CY decreases the cell
number and functionality of TREGs, which may enhance its anti-
tumor activity (59). Therefore, the combination of low-dose CY
and MVA-5T4 is a potentially successful strategy to overcome the
immune tolerance of mRCC by enhancing the killing effect of the
immune system at least at two different levels.
Treatment of mRCC has improved greatly over the past
decade with the approval of multiple molecular-targeted therapies,
including sunitinib, sorafenib, and temsirolimus, among others
(60). Sunitinib is a multitargeted tyrosine kinase inhibitor that
predominantly targets vascular endothelial growth factor (VEGF).
In addition to its anti-VEGF activity, sunitinib has activity in
suppressing TREGs, so it is an ideal compound to combine with
MVA-5T4 to treat mRCC. Although this combination was studied
in one of the three arms of the aforementioned phase III trial,
given the problems of that study design and the strong scientific
rationale, it is worth retesting this combination.
Finally, the rapid progression in targeted drug develop-
ment represents a great opportunity to improve the clinical
benefit of patients with cancer. Ipilimumab (anti-cytotoxic T-
lymphocyte-associated antigen 4), anti-programed death 1, and
anti-programed death ligand 1 represent a new family of targeted
therapies that inhibit the inhibitory checkpoints of the immune
system (61–63). The combination of MVA-5T4 and these novel
immunomodulator drugs could be a good strategy to overcome
cancer immune tolerance.
In conclusion, MVA-5T4 (TroVax®) is a novel vaccine ther-
apy that has been proven safe and could potentially impact the
treatment of various solid tumors, including RCC. Well-designed
clinical trials based of both biomarkers and combinations with
other and new immunomodulator agents are needed.
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